Clinical trial · Observational
Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma
Chemotherapy Combined with Immunotherapy and Targeted Therapy in Advanced Intrahepatic Cholangiocarcinoma
NCT06718257CI-TRIAL-00085603recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to validate the efficacy and safety of GP/GEMOX combined with PD-1/L1 inhibitors and TKI agents in patients with advanced cholangiocarcinoma through a multicenter, retrospective study to guide clinical practice.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cholangiocarcinoma | Cholangiocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gemcitabine combined with cisplatin or oxaliplatin | Drug | — | UNRESOLVED |
| Gemcitabine combined with cisplatin or oxaliplatin, PD-1/L1 and TKI inhibitors | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Control group
- description
- Patients initially received GP/GEMOX regimen.
- interventionNames
- Drug: Gemcitabine combined with cisplatin or oxaliplatin
- label
- Experimental group
- description
- Patients initially received GP/GEMOX combined with PD-1/L1 and TKI inhibitors regimen.
- interventionNames
- Drug: Gemcitabine combined with cisplatin or oxaliplatin, PD-1/L1 and TKI inhibitors
Primary outcomes (1)
- measure
- Overall survival (OS)
- timeFrame
- 1 year
- description
- Overall survival (OS) is defined as the time from cancer diagnosis to death from any cause.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or radiologically confirmed intrahepatic cholangiocarcinoma * Initially treated with GP/GEMOX or GP/GEMOX combined with PD-1/L1 and TKI inhibitors Exclusion Criteria: * Direct surgery after hospitalization * Initial treatment combined with local therapies (radiotherapy, radiofrequency, particle implantation, TACE, etc.) * Initial treatment involving other comprehensive therapeutic regimens
References
Publications (0)
Data not yet available
No reference posted for this study.